Nordion announced results from its Phase 2 multisite clinical trial of TheraSphere for the treatment of metastatic liver cancer. The trial evaluated safety and tumor response in 151 patients with liver metastases. Results showed that the overall tumor response, including stable disease, was 90% in metastatic neuroendocrine tumors and 69.2% in all treatment groups.
TheraSphere is a liver cancer therapy that consists of millions of small glass beads (20–30 micrometers in diameter) containing radioactive yttrium-90 (Y-90). It is indicated for radiation treatment or as a neoadjuvant to surgery or transplantation in patients with unresectable hepatocellular carcinoma (HCC) who can have placement of appropriately positioned hepatic arterial catheters. The device is also indicated for HCC patients with partial or branch portal vein thrombosis/occlusion, when clinical evaluation warrants the treatment.
For more information call (800) 267-6211 or visit www.nordion.com.